Improvement in aGVHD severity with donor-derived MSCs and Treg cells.

<p>Recipient mice (BALB/c, H-2^d) were irradiated with 800 cGy and injected intravenously (i.v.) with 5×10⁶ BMCs and 5×10⁶ spleen cells from donor mice (C57BL/6, H-2^b) and donor-derived MSCs (1×10⁶) and C57BL/6 background eGFP mice-derived Treg cells (2×10⁶) on days 0 and 4, and mice were evaluated at different time points after BMT (<i>n</i> = 10). (A) Increase in survival rate in aGVHD mice model after co-administration of MSCs and Treg cells in allogeneic transplantation. (B–C) The degree of clinical aGVHD was assessed weekly using a scoring system that summed changes in five clinical parameters: weight loss, posture, activity, fur texture, and skin integrity. (D) Histological scores were evaluated in aGVHD target organs: skin (200×), liver (200×), and small intestine (200×). Data are shown as the mean ± SEM. The results are representative of three independent experiments. <i>P</i> values were determined using Student’s <i>t</i>-test. * <i>p</i> < 0.05, ** <i>p</i> < 0.01.